Sanofi India Limited has informed the Exchange about Investor Presentation
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India shared its Q4 and FY25 results presentation with the exchanges. Total income fell 9% YoY to ₹18,571 million for FY25, but net sales were flat to slightly up at ₹15,115 million (+1%), with domestic sales steady. Operating expenses were cut sharply by 17% in both Q4 and the full year versus 2024, helping profit before tax grow 1% to ₹4,720 million despite weak revenue, and lifting PBT margin from 25% to 27%. Q4 was weaker, with net sales down 7% to ₹3,490 million and PBT down 27% to ₹830 million. The company highlighted its diabetes franchise, where it holds a 31% market share with 6% volume growth, and discussed pipeline molecules like Teplizumab, Brivekimig and Frexalimab. A dividend of ₹123 per share was proposed for FY25, a 5% increase over FY24, with a payout ratio of around 87%.
Flat topline but stronger margins and lower costs should support earnings stability; however, the sharp Q4 profit decline and a premium valuation may limit near-term upside, while the higher dividend is a positive signal for shareholders.